SCHEMBL6905904

SCHEMBL6905904

CCCOC(=O)CN(C=O)c1ccc(OC(C)=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MAPT P10636 6/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 6/20 0.37
MEN1 O00255 3/20 0.37
KDM4E B2RXH2 2/20 0.37
CYP3A4 P08684 2/20 0.37
TTR P02766 1/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ELANE P08246 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ESR1 P03372 1/20 0.36
HSD17B10 Q99714 2/20 0.36
OPRK1 P41145 1/20 0.35
ALDH1A1 P00352 3/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6906705 0.89 LMNA (0.46) LMNAMAPTPOLBPKMKMT2A
SCHEMBL6902209 0.84 ALOX15 (0.44) LMNAKMT2AMEN1CYP3A4HPGD
SCHEMBL6907195 0.84 KMT2A (0.45) LMNAMAPTPOLBPKMKMT2A
SCHEMBL6908413 0.83 LMNA (0.40) LMNAMAPTPOLBPKMKMT2A
SCHEMBL6905457 0.81 LMNA (0.38) LMNAMAPTPOLBPKMKMT2A
SCHEMBL6902830 0.81 LMNA (0.46) LMNAMAPTPOLBPKMKMT2A
SCHEMBL6908787 0.77 TDP1 (0.45) LMNAKMT2AMEN1KDM4EESR1
SCHEMBL8337596 0.75 GAA (0.49) LMNAKMT2AKDM4ESMN1; SMN2L3MBTL1
SCHEMBL8984333 0.73 L3MBTL1 (0.56) LMNAMAPTPOLBPKMKMT2A
SCHEMBL6905593 0.73 LMNA (0.48) LMNAMAPTPOLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 LMNA 1347/4885MAPT 4452/4885POLB 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.